Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021 | Regeneron Pharmaceuticals Inc.

TARRYTOWN, N.Y., Jan. 19, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Friday, February 5, 2021, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Post a Press Release

Browse Top 1000 Lists

Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International), conference ID 1580376.  A link to the webcast may be accessed from the ‘Investors and Media’ page of Regeneron’s website at  A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days. 

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

More:  Dupixent® (dupilumab) Efficacy and Safety in Patients as Young as Six Years with Moderate-to-severe Atopic Dermatitis Further Reinforced by New Analyses Presented at EADV | Regeneron Pharmaceuticals Inc.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit or follow @Regeneron on Twitter.

Contact Information:
Investor RelationsJustin Holko914.847.7786

Corporate CommunicationsHala Mirza914.847.3422

Cision View original content:

SOURCE Regeneron Pharmaceuticals, Inc.

More from: | Category: Pharmaceutical Company News